How SCFAs modulate cardiometabolic disease risk by interacting with an individual’s adiposity parameters and diet.
Humira and Stelara continue to lead specialty drug spending, but newer drugs like Keytruda, Skyrizi are closing in — report
Spending on specialty drugs continues to grow, driven mostly by more people using them, but also by increasing prices. Specialty drug spending jumped 14.1% year
August 2, 2023